trending Market Intelligence /marketintelligence/en/news-insights/trending/meeelw_d3jeq4lgg3hqmtw2 content esgSubNav
In This List

Cara Therapeutics director resigns

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cara Therapeutics director resigns

Cara Therapeutics Inc. said Dean Slagel submitted his resignation as director with effect from March 7.

Slagel was the longest tenured director of the company, having joined the board in 2005, the biopharma said in an SEC filing.

Stamford, Conn.-based Cara Therapeutics is a clinical-stage biopharmaceutical company which focuses on developing and marketing pain management therapies.